{"id":"NCT04450329","sponsor":"Samsung Bioepis Co., Ltd.","briefTitle":"A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)","officialTitle":"A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB15 (Proposed Aflibercept Biosimilar) and Eylea® in Subjects With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-23","primaryCompletion":"2021-04-15","completion":"2022-03-16","firstPosted":"2020-06-29","resultsPosted":"2024-02-05","lastUpdate":"2024-02-05"},"enrollment":449,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"SB15 (Proposed aflibercept biosimilar)","otherNames":[]},{"type":"DRUG","name":"Eylea (Aflibercept)","otherNames":[]}],"arms":[{"label":"SB15 (Proposed aflibercept biosimilar)","type":"EXPERIMENTAL"},{"label":"Eylea (Aflibercept)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.","primaryOutcome":{"measure":"Change From Baseline in Best Corrected Visual Acuity (BCVA)","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"SB15 (Proposed Aflibercept Biosimilar)","deltaMin":6.7,"sd":0.56},{"arm":"Eylea (Aflibercept)","deltaMin":6.6,"sd":0.57}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["United States","Croatia","Czechia","Estonia","Hungary","Japan","Latvia","Poland","Russia","South Korea"]},"refs":{"pmids":["37289448"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":224},"commonTop":["Neovascular age-related macular degeneration","Visual acuity reduced"]}}